Consensus classification of posterior cortical atrophy

<h4>Introduction</h4> <p>A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings.</p> <h4>Methods</h4> <p>Consensus statements about PCAwere develo...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Crutch, S, Schott, J, Rabinovici, G, Murray, M, Snowden, J, , v, Dickerson, B, Vandenberghe, R, Ahmed, S, Bak, T, Boeve, B, Butler, C, Cappa, S, Ceccaldi, M, de Souza, L, Dubois, B, Felician, O, Galasko, D, Graff-Radford, J, Graff-Radford, N, Hof, P, Krolak-Salmon, P, Lehmann, M, Magnin, E, Mendez, M, Nestor, P, Onyike, C, Pelak, V, Pijnenburg, Y, Primativo, S, Rossor, M, Ryan, N, Scheltens, P, Shakespeare, T, Suárez González, A, Tang-Wai, D, Yong, K, Carrillo, M, Fox, N
Formaat: Journal article
Taal:English
Gepubliceerd in: Elsevier 2017
Omschrijving
Samenvatting:<h4>Introduction</h4> <p>A classification framework for posterior cortical atrophy (PCA) is proposed to improve the uniformity of definition of the syndrome in a variety of research settings.</p> <h4>Methods</h4> <p>Consensus statements about PCAwere developed through a detailed literature review, the formation of an international multidisciplinary working party which convened on four occasions, and a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA.</p> <h4>Results</h4> <p>A three-level classification framework for PCA is described comprising both syndromeand disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attributable to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD], prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome severity and characterizing phenotypic heterogeneity within the PCA spectrum.</p> <h4>Discussion</h4> <p>There was strong agreement regarding the definition of the core clinico-radiological syndrome, meaning that the current consensus statement should be regarded as a refinement, development, and extension of previous single-center PCA criteria rather than any wholesale alteration or redescription of the syndrome. The framework and terminology may facilitate the interpretation of research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral interventions, pharmacological trials), and provide a foundation for future collaborative work.</p>